Daptomycin

證據等級: L5

預測適應症: 10 個

Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis

One-Sentence Summary

Daptomycin is a cyclic lipopeptide antibiotic approved for treating serious Gram-positive bacterial infections, including complicated skin and soft tissue infections, Staphylococcus aureus bacteremia, and right-sided infective endocarditis. The TxGNN model predicts it may be effective for Osteoarthritis with a score of 99.86%, supported by 0 clinical trials and 9 associated publications — however, evidence review indicates this is a false positive driven by literature co-occurrence in patients undergoing joint replacement surgery rather than a genuine repurposing signal. Of the top 10 predictions, Rheumatoid Arthritis (Rank 2, score 99.84%, Evidence Level L4) carries the most scientifically credible mechanistic basis, supported by two 2025 preclinical studies demonstrating NF-κB pathway suppression in collagen-induced arthritis models.

Quick Overview

Item	Content
Original Indication	Gram-positive bacterial infections (complicated skin/soft tissue infections, S. aureus bacteremia, right-sided endocarditis)
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	99.86%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Daptomycin is a cyclic lipopeptide antibiotic that disrupts bacterial cell membrane integrity in a calcium-dependent manner — it binds to phosphatidylglycerol in the membrane, causing depolarization and rapid bactericidal cell death. This mechanism is unique among antibiotics and specifically targets Gram-positive organisms including MRSA and VRE. It has no known action on eukaryotic cell signaling pathways relevant to inflammatory joint disease.

Osteoarthritis is driven by progressive cartilage degradation, synovial inflammation, and subchondral bone remodeling — pathways mediated by TGF-β, Wnt/β-catenin, MMP-13, and ADAMTS signaling. Daptomycin has no established activity in any of these pathways. There is no pharmacological rationale connecting an antibiotic membrane depolarizer to OA disease modification.

The high TxGNN score is best explained as a literature co-occurrence false positive: all 9 retrieved publications describe Daptomycin being used to treat periprosthetic joint infections (PJIs) and osteoarticular infections in patients who had previously undergone joint replacement surgery — a common outcome in advanced OA. These studies address bacterial infection management, not OA treatment. The knowledge graph has learned an association between Daptomycin and "osteoarthritis" from this incidental clinical overlap, not from any true therapeutic connection.

Clinical Trial Evidence

Currently no related clinical trials registered for Daptomycin in osteoarthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
17999973	2008	Retrospective comparative	J Antimicrob Chemother	Daptomycin vs. standard therapy for osteoarticular infections associated with S. aureus bacteremia — evaluates antibiotic treatment outcomes, not OA disease modification
21477701	2010	Registry analysis	Medicina Clinica	EU-CORE registry real-world daptomycin use in Spain, including osteoarticular infection patients — routine antibiotic usage data
22511636	2012	Retrospective cohort	J Antimicrob Chemother	Daptomycin for hip and knee periprosthetic joint infections — clinical efficacy and safety as an antibiotic in post-arthroplasty patients
22854340	2012	In vitro susceptibility	J Antibiotics	Susceptibility of S. aureus and S. epidermidis isolated from prosthetic joint infections to daptomycin — microbiological susceptibility mapping
23312602	2013	Cross-sectional survey	Int J Antimicrob Agents	Physician survey on PJI antibiotic practices; daptomycin cited as preferred option for MRSA PJI — clinical practice guidance, not OA therapy
23519823	2013	Retrospective cohort	Int Orthop	High-dose daptomycin + rifampicin combination for Gram-positive osteoarticular infections — antibiotic regimen safety and efficacy
25650692	2015	Retrospective epidemiology	Surgical Infections	Microbiologic profile of staphylococci from osteoarticular infections over 10 years — antibiotic susceptibility trends to inform empiric therapy
26235888	2015	Retrospective cohort	Int J Antimicrob Agents	High-dose daptomycin (>6 mg/kg) for complicated bone and joint implant-associated infections — dosing safety data
32206362	2020	Case report	Case Reports in Orthopedics	C. striatum septic arthritis misdiagnosed as OA; daptomycin used to treat the infection — highlights diagnostic overlap, not OA treatment

⚠️ Critical Interpretation Note: All 9 publications address Daptomycin as an antibiotic for joint infections occurring in patients with osteoarthritis or post-arthroplasty. None study Daptomycin as a therapy for OA pathology itself. This literature pattern is the mechanistic source of the TxGNN false positive.

Singapore Market Information

Daptomycin is currently not registered or marketed in Singapore. No product authorizations are on file.

For reference, Daptomycin (brand name Cubicin®) is approved in the United States, European Union, and other markets for Gram-positive bacterial infections including MRSA. Any future registration in Singapore would require a new HSA application.

Safety Considerations

Please refer to the package insert for comprehensive safety information, as formal warning and contraindication data were not available in this Evidence Pack.

Based on published literature, the following safety signals are particularly relevant to any repurposing consideration:

Myotoxicity (High concern for chronic use): Daptomycin is associated with elevated creatine kinase (CK), myopathy, and rhabdomyolysis — risk increases with higher doses and prolonged administration. A documented case (PMID 36693494) reports daptomycin-induced rhabdomyolysis complicated by acute secondary gouty arthritis. This toxicity profile is incompatible with the long-term treatment required for OA or RA.
Pulmonary toxicity: Eosinophilic pneumonia has been reported with daptomycin use, requiring treatment discontinuation.
Route of administration barrier: Daptomycin is administered intravenously only. This is a fundamental barrier for any chronic musculoskeletal indication.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN high-score prediction for osteoarthritis is assessed as a false positive resulting from knowledge graph co-occurrence, not a true repurposing signal. Daptomycin has no mechanistic basis for OA disease modification, zero clinical trials, and zero preclinical OA models. All associated literature describes antibiotic use in OA patients with secondary joint infections — a clinically incidental association.

Secondary Finding Warranting Monitoring — Rheumatoid Arthritis (Rank 2, L4):

Two 2025 publications (PMID 39571268, 40923559) directly demonstrate Daptomycin's anti-inflammatory activity in the collagen-induced arthritis (CIA) mouse model — the gold-standard preclinical model for RA drug development. The proposed mechanism is inhibition of the NF-κB signaling pathway with downstream suppression of TNF-α, IL-1β, IL-6, and IL-17. One group has already synthesized novel Daptomycin-derived cyclic lipopeptide analogs with improved anti-RA activity (CLP-d2), suggesting active structural optimization efforts. This constitutes genuine early-stage mechanistic evidence and merits tracking as a research question.

To advance the RA research question, the following is needed:

Evaluation of anti-inflammatory dosing vs. antibacterial dosing to determine therapeutic window
Long-term safety data in chronic administration animal models (myotoxicity is the primary barrier)
Investigation of Daptomycin-derived structural analogs (e.g., CLP-d2) that dissociate anti-inflammatory from myotoxic effects
In vitro human synoviocyte and PBMC validation studies
A clear regulatory pathway assessment, given no Singapore registration and IV-only formulation

Research Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.